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doi:10.1016/j.kjms.2012.02.003Abstract Without surgery, it is hard to predict the histology of small (& 4 cm) renal masses
(SRMs) based on images. This study attempted to investigate whether clinical parameters were
correlated with the pathological presence of SRM carcinomas. We conducted a retrospective
chart review of 60 patients with 61 suspicious SRMs on radiological examination who received
radical nephrectomy (RN) or partial nephrectomy (PN) between January 2003 and February
2011 in the China Medical University Hospital (CMUH). The correlations between patient age,
gender, tumor size, and pathological features were calculated and analyzed. Of the 61 SRMs,
there were 51 (83.6%) renal cell carcinoma (RCC), seven (11.5%) angiomyolipoma, two (3.3%)
oncocytoma, and one (1.6%) metanephric adenoma. Regarding the histological variants of these
cases of RCC, 44 were categorized as the clear cell type, two as the papillary type, and five as
the chromophobe type. The incidence of benign tumor was greater in females (pZ 0.014) and
tumor size 2 cm or less (pZ 0.02), compared with males and tumor size more than 2 cm,
respectively. Surgical intervention is generally recommended for medically fit patients.
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The detection of small renal mass (SRM) has increased
greatly given the widespread use of diagnostic imaging
modalities including sonography, computed tomography
(CT), and magnetic resonance imaging (MRI). Of SRM cases,
approximately 80% were malignant and 20% were benigned.
Table 1 Demographics and pathological features of small
renal mass (SRM) cases.
Partial
nephrectomy
Radical
nephrectomy
p
No. of SRMs 51 10
Mean age at surgery
(range)
57.8 (34e83) 57.1 (26e86) 0.891
Mean cm tumor size
(range)
2.9 (1.5e4) 3.1 (2.2e4) 0.409
No. of gender (%)
Females 21 (41.2) 5 (50.0) 0.731
Males 30 (58.8) 5 (50.0)
No. of histological subtype (%)
Clear cell RCC 36 (70.6) 8 (80.0)
Papillary RCC 1 (2.0) 1 (10.0)
Chromophobe RCC 4 (7.8) 1 (10.0)
AML 7 (13.7) 0
Oncocytoma 2 (3.9) 0
Metanephric
adenoma
1 (2.0) 0
AMLZ angiomyolipoma; RCCZ renal cell carcinoma; SRMZ
small renal mass.
Table 2 Comparison of clinical parameters between
benign tumors and renal cell carcinoma (RCC).
Benign tumor RCC p
No. of SRMs (%) 10 (16.4) 51 (83.6)
Mean age at surgery
(range)
53.8 (39e74) 58.4 (26e86) 0.354
Mean cm tumor size
(range)
2.4 (1.5e3.5) 3.1 (1.5e4) 0.012*
No. of gender (%)
Females 8 (80.0) 18 (35.3) 0.014*
Males 2 (20.0) 33 (64.7)
No. of nephrectomy (%)
PN 10 (100) 41 (80.4) 0.191
RN 0 (0) 10 (19.6)
PNZ partial nephrectomy; RCCZ renal cell carcinoma;
RNZ radical nephrectomy; SRMZ small renal mass.
* p < 0.05.
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that conclusively identified a mass as malignant or benign
[8,9]. Until recently, several studies with small sample sizes
have demonstrated the differentiation between oncocy-
toma and renal cell carcinoma (RCC) based on multiphase
CT [10,11]. Owing to the lack of precise diagnosis by non-
invasive measures, various treatment options such as
active surveillance, needle biopsy, tumor ablation, and
nephrectomy have been proposed. The choice of treatment
strategy depends on patients’ age, renal function, and
comorbidities [9].
As the literature is limited concerning SRM in Taiwan
[12], this study was conducted to investigate the pathology
of SRMs with suspicion of malignancy and assess relevant
clinical parameters.
Materials and methods
We retrospectively reviewed the medical records of
patients receiving partial nephrectomy (PN) or radical
nephrectomy (RN) between January 2003 and February
2011 in the China Medical University Hospital (CMUH).
There were 60 patients with 61 renal masses with a size of
4 cm or less. All the renal masses were localized, sporadic,
solid, and enhanced on CT or MRI. Owing to a suspicion of
malignancy, the renal masses were surgically resected. In
addition to the imperative indications such as bilateral
renal masses, atrophic opposite kidney, and compromised
renal function, PN was also performed electively in patients
with normal opposite kidney. However, RN was reserved for
renal masses located in the renal hilum or with central sinus
invasion. No biopsy or ablation was done preoperatively.
After the operation, the pathological features were
reviewed by experienced pathologists.
Clinicopathological features among different surgical
strategies and tumor histology were compared using the
Student t test and Fisher’s exact test. Statistical analyses
were performed using the Statistical Product and Service
Solution (SPSS, version 17.0, SPSS Inc., Chicago, Illinois,
USA), and a p< 0.05 was considered statistically significant.
The protocol of this study was approved by the Ethic
Committee of CMUH.
Results
Among the 61 SRM cases, the mean age at surgery was 57.7
years (range 26e86 years). The mean tumor size was 3.0 cm
(range 1.5e4 cm). Thirty-five patients (57.4%) were male
and twenty-six (42.6%) were female. One female patient
received bilateral PN for bilateral SRM. Table 1 lists the
demographics and pathological features of all SRM cases,
stratified by surgical modalities. PN and RN were performed
for 51 and 10 SRM cases, respectively. There was no
significant difference in age at surgery, tumor size, and
gender between patients receiving PN or RN. Of the 61 SRM,
there were 51 RCC, seven angiomyolipoma (AML), two
oncocytoma, and one metanephric adenoma. Regarding the
histological variants of the cases of RCC, 44 were catego-
rized as the clear cell type, two as the papillary type, and
five as the chromophobe type. One patient in our study
cohort was an Italian whose SRM was oncocytoma.Table 2 shows the comparison of clinical parameters
between benign tumors and RCC. Of the 26 females, eight
(30.8%) had benign tumors compared with two of the 35
males (5.7%; pZ 0.014). The mean diameter of benign
tumor was smaller than that of RCC (2.4 cm versus 3.1 cm,
pZ 0.012). Age at surgery and modality of surgery were not
significantly correlated with the incidence of RCC among
SRM cases. To further clarify the influence of size and gender
on tumor histology, we adopted 2 cm as a cutoff value (Table
3) and found that benign tumor wasmore common in the SRM
with a size of 2 cm or less (50.0% versus 11.3%, pZ 0.02). In
addition, for SRM with a size of 2 cm or less, the incidence of
benign histology remained greater in females than in males
(75% versus 25% respectively, Table 3), although the case
numbers were too small to reach statistical significance.
Table 3 Histology of small renal mass (SRM) stratified by
tumor sizea and gender.
Benign tumor RCC
Size & 2 cm
No. of gender (%)b 4 4
Females 3 (75) 1 (25)
Males 1 (25) 3 (75)
Size > 2 cm
No. of gender (%) 6 47
Females 5 (83.3) 17 (36.2)
Males 1 (16.7) 30 (63.8)
RCCZ renal cell carcinoma; SRMZ small renal mass.
a Of the eight SRMs with size & 2 cm, four (50%) were benign
tumors compared with six of the 53 SRMs with size > 2 cm
(11.3%, pZ 0.02).
b For SRMs with size& 2 cm, 75% of females had benign tumor
compared with 25% of males, although the case numbers were
too small to reach statistical significance.
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Because the clinical manifestations were nonspecific and
the false negative rate of needle biopsy was high (negative
predictive value for renal mass &3 cm, 60%) [13], imaging
studies played an indispensable role in evaluating SRM. On
CT scan, a small RCC typically exhibits a homogeneously
isodense/hypodense, noncalcified, and well-enhanced
mass, with an attenuation value of 20 Hounsfield unit
(HU) or more [14]. It is difficult to differentiate oncocytoma
from clear cell RCC because both of them enhance avidly,
and the classical central stellate scar is present in less than
half of the cases of oncocytoma [15]. Besides, lipid-poor
AML enhances moderately, similar to chromophobe RCC
[15]. As for MRI, by the threshold of 15% increase in the
signal intensity on T1-weighted images, the sensitivity and
specificity to distinguish malignant from benign renal
masses were 95% and 53%, respectively. The inability to
distinguish oncocytoma from RCC leads to the low speci-
ficity [16]. Recently, Gakis et al. reported that oncocytoma
showed greater isodensity to the normal renal cortex in the
corticomedullary phase, compared to clear cell RCC [10].
Bird et al. demonstrated that oncocytoma showed an
enhancement of more than 500% in the arterial phase and
wash-out values of greater than 50% [11]. Nevertheless, the
results of these two studies may be limited by small sample
size and selection bias.
Although it is difficult to differentiate a benign tumor
from malignancy based on images only, tumor size has been
suggested to be significantly correlated with pathological
feature. In our study, RCC accounts for 83.6% of SRM cases
with suspicion of malignancy, compatible with previously
reported incidences of malignancy around 80% [1e7]. As the
size of a solid renal tumor decreases, the tumor is more
likely to be benign. Frank et al. found the incidence of RCC
among tumors less than 1 cm was 53.8%, and each 1 cm
increase in size carried 17% increase in the odds of malig-
nancy [1]. Furthermore, larger malignant tumors were more
likely to be the clear cell type and have higher nuclear grade
[1]. In our cohort, we also found an SRM of 2 cm or less wasmore likely to have benign histology than an SRM greater
than 2 cm (50% versus 11.3%, pZ 0.02, Table 3).
Regarding the surgical outcome, more than 95% of 5-year
cancer-specific survival rates have been reported in
patients with pathological stage T1a (pT1a) tumors under-
going RN or PN [17,18]. Due to the high incidence of RCC
and good surgical outcome, surgical intervention has
generally been recommended for suspicious SRM. However,
some recent studies have found development of SRM
often follows an indolent course, making active surveil-
lance a reasonable option in elderly patients or surgical
candidates under poor conditions [19e21]. Especially for
SRMs of 2 cm or less, owing to much higher incidence of
benign histology, active surveillance may obviate more
unnecessary treatment-induced morbidities. In a meta-
analysis of 6471 SRMs, Kunkle et al. found no difference
in the incidence of metastatic progression regardless of
whether SRM was excised, ablated, or observed [22].
Jewett et al. also found delaying treatment until the SRM
progresses exerted no adverse effect on the oncological
outcome [23]. However, there is still a lack of a safety
cutoff size for active surveillance, given the metastatic
potential and various comorbidities [24]. The incidence of
local progression has been reported at 12% and metastatic
progression at about 1% in the first 2 years of follow-up
[23,24]. Patients choosing active surveillance must be
informed of this low but non-negligible risk of progression.
As for imaging follow-up, Jewett et al. suggested serial
ultrasonography, CT, or MRI every 3 months in the first year
followed by a decreasing frequency to an annual interval by
the 3rd year and thereafter [23]. In summary, patient age,
renal function, comorbidities, personal preference, and
surgical risk have to be considered in the treatment plan-
ning. Future studies regarding the prognostic factors for
RCC are best needed to stratify patients with SRM into
different risk groups and clarify the best treatment
strategy.
The most common benign lesion of suspicious SRM in our
study was AML, which was similar to findings in the Japa-
nese and Korean cohorts [2,3]. By contrast, the most
common benign lesion is oncocytoma in the Western
countries (Table 4) [4e6]. Interestingly, one of the onco-
cytomas in our study was of Italian origin. Thus, there may
exist some racial differences in the incidence of oncocy-
toma. In addition, the incidence of benign tumor was
greater in females than in males (30.8% and 5.7%, respec-
tively, pZ 0.014). Snyder et al. also reported that women
were associated with almost twice the chance of having
a benign renal lesion compared with men [7]. The influence
of gender on benign histology may be explained by the
female predominance in AML.
There are several limitations in our study. This is
a retrospective and single-institutional study. The number
of patients was relatively smaller than in other studies, and
therefore the validity of our results may be insufficient.
Because the study cohort included almost exclusively
Taiwanese patients, the results may not be generalized to
other ethnic groups. Furthermore, those patients with SRM
receiving active surveillance were not included in our
study, leading to a selection bias. Nevertheless, we offer
experiences in Taiwan regarding the pathology of SRM and
have demonstrated the significance of the female gender
Table 4 Reported incidence of benign small renal mass (SRM).
Country Year N Benign
SRM (%)
AML (%) Oncocytoma
(%)
Complicated
cyst (%)
Others
(%)
Present study Taiwana 2003e2011 61 10 (16.4) 7 (11.5) 2 (3.3) 0 1 (1.6)
Fujii et al2 Japan 1993e2007 176 19 (10.8) 10 (5.7) 5 (2.8) 2 (1.1) 2 (1.1)
Jeon et al3 Korea 1997e2008 376 81 (21.5) 35 (9.3) 11 (2.9) 26 (6.9) 9 (2.4)
Pahernik et al4 Germany 1979e2004 504 122 (24.2) 33 (6.5) 53 (10.5) 23 (4.6) 13 (2.8)
McKiernan et al5 USA 1989e2002 281 65 (23.1) 12 (4.3) 32 (11.4) 16 (5.7) 5 (1.8)
Gill et al6 USA 1999e2001 200 45 (22.5) 8 (4) 26 (13) 3 (1.5) 8 (4)
AMLZ angiomyolipoma; SRMZ small renal mass.
a There was one Italian in the present study whose SRM was oncocytoma.
372 P.-F. Hsieh et al.and small tumor volume on benign histology. Larger-scaled
and prospective studies are needed to support the findings.
Conclusions
According to our experience, 83.6% of suspicious SRM cases
in Taiwan are malignant. Being female or having a tumor
size of 2 cm or less implies greater probability of benign
histology. Surgical intervention is generally recommended
for medically fit patients. Larger-scaled and prospective
studies are needed to support the findings.
References
[1] Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H.
Solid renal tumors: an analysis of pathological features
related to tumor size. J Urol 2003;170:2217e20.
[2] Fujii Y, Komai Y, Saito K, Iimura Y, Yonese J, Kawakami S, et al.
Incidence of benign pathologic lesions at partial nephrectomy
for presumed RCC renal masses: Japanese dual-center experi-
ence with 176 consecutive patients. Urology 2008;72:598e602.
[3] Jeon HG, Lee SR, Kim KH, Oh YT, Cho NH, Rha KH, et al.
Benign lesions after partial nephrectomy for presumed renal
cell carcinoma in masses 4 cm or less: prevalence and
predictors in Korean patients. Urology 2010;76:574e9.
[4] Pahernik S, Roos F, Hampel C, Gillitzer R, Melchior SW,
Thu¨roff JW. Nephron sparing surgery for renal cell carcinoma
with normal contralateral kidney: 25 years of experience. J
Urol 2006;175:2027e31.
[5] McKiernan J, Yossepowitch O, Kattan MW, Simmons R,
Motzer RJ, Reuter VE, et al. Partial nephrectomy for renal
cortical tumors: pathologic findings and impact on outcome.
Urology 2002;60:1003e9.
[6] Gill IS, Matin SF, Desai MM, Kaouk JH, Steinberg A, Mascha ED,
et al. Comparative analysis of laparoscopic versus open partial
nephrectomy for renal tumors in 200 patients. J Urol 2003;
170:64e8.
[7] Snyder ME, Bach A, Kattan MW, Raj GV, Reuter VE, Russo P.
Incidence of benign lesions for clinically localized renal
masses smaller than 7 cm in radiological diameter: influence
of sex. J Urol 2006;176:2391e6.
[8] Cary KC, Sundaramm CP. Watchful waiting in the treatment of
the small renal mass. Indian J Urol 2009;25:489e93.
[9] Gill IS, Aron M, Gervais DA, Jewett MA. Small renal mass. N
Engl J Med 2010;362:624e34.
[10] Gakis G, Kramer U, Schilling D, Kruck S, Stenzl A,
Schlemmer HP. Small renal oncocytoma: differentiation with
multiphase CT. Eur J Radiol 2011;80:274e8.[11] Bird VG, Kanagarajah P, Morillo G, Caruso DJ, Ayyathurai R,
Leveillee R, et al. Differentiation of oncocytoma and renal cell
carcinoma in small renal mass (<4 cm): the role of 4-phase
computerized tomography. World J Urol 2011;29:787e92.
[12] Lui KW, Gervais DA, Arellano RA, Mueller PR. Radiofrequency
ablation of renal cell carcinoma. Clin Radiol 2003;58:905e13.
[13] Rybicki FJ, Shu KM, Cibas ES, Fielding JR, van Sonnenberg E,
Silverman SG. Percutaneous biopsy of renal masses: sensitivity
and negative predictive value stratified by clinical setting and
size of masses. Am J Roentgenol 2003;180:1281e7.
[14] Silverman SG, Lee BY, Seltzer SE, Bloom DA, Corless CL,
Adams DF. Small (< or Z 3 cm ) renal masses: correlation of
spiral CT features and pathologic findings. Am Journal
Roentgenol 1994;163:597e605.
[15] Zhang J, Lefkowitz RA, Ishill NM, Wang L, Moskowitz CS,
Russo P, et al. Solid renal cortical tumors: differentiation with
CT. Radiology 2007;244:494e504.
[16] Hecht EM, Israel GM, Krinsky GA, Hahn WY, Kim DC, Belitskaya-
Levy I, et al. Renal masses: quantitative analysis of enhance-
ment with signal intensity measurements versus qualitative
analysis of enhancement with image subtraction for diagnosing
malignancy at MR imaging. Radiology 2004;232:373e8.
[17] Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM,
Zincke H. Independent validation of the 2002 American joint
committee on cancer primary tumor classification for renal
cell carcinoma using a large, single institution cohort. J Urol
2005;173:1889e92.
[18] Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for
localized renal cell carcinoma: impact of tumor size on
patient survival, tumor recurrence and TNM staging. J Urol
1999;162:1930e3.
[19] Russo P, Jang TL, Pettus JA, Huang HC, Eggener SE,
O’Brien MF, et al. Survival rates after resection for localized
kidney cancer: 1989 to 2004. Cancer 2008;113:84e96.
[20] Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK.
Rising incidence of small renal masses: a need to reassess
treatment effect. J Natl Cancer Inst 2006;98:1331e4.
[21] Jewett MA, Zuniga A. Renal tumor natural history: the ratio-
nale and role for active surveillance. Urol Clin North Am 2008;
35:627e34.
[22] Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe:
the small renal mass dilemmada meta-analysis and review. J
Urol 2008;179:1227e33.
[23] Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE,
Siemens DR, et al. Active surveillance of small renal masses:
progression patterns of early stage kidney cancer. Eur Urol
2011;60:39e44.
[24] Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY,
Uzzo RG. The natural history of observed enhancing renal
masses: meta-analysis and review of the world literature. J
Urol 2006;175:425e31.
